Journal article
Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine
Hannah Mary Cheeseman, Suzanne Day, Leon Robert McFarlane, Sue Fleck, Aleisha Miller, Tom Cole, Nelson Sousa-Santos, Alethea Cope, Deniz Cizmeci, Monica Tolazzi, Edith Hwekwete, Drew Hannaman, Sven Kratochvil, Paul Francis McKay, Amy W Chung, Stephen J Kent, Adrian Cook, Gabriella Scarlatti, Sonya Abraham, Behazine Combadiere Show all
HUMAN GENE THERAPY | MARY ANN LIEBERT, INC | Published : 2018
DOI: 10.1089/hum.2018.075
Abstract
Intradermal (i.d.) and intramuscular (i.m.) injections when administered with or without electroporation (EP) have the potential to tailor the immune response to DNA vaccination. This Phase I randomized controlled clinical trial in human immunodeficiency virus type 1-negative volunteers investigated whether the site and mode of DNA vaccination influences the quality of induced cellular and humoral immune responses following the DNA priming phase and subsequent protein boost with recombinant clade C CN54 gp140. A strategy of concurrent i.d. and i.m. DNA immunizations administered with or without EP was adopted. Subtle differences were observed in the shaping of vaccine-induced virus-specific ..
View full abstractRelated Projects (1)
Grants
Awarded by European Union's Seventh Programme for research, technological development, and demonstration
Awarded by Wellcome Trust via UKHVC
Awarded by European Union's Horizon 2020 research and innovation programme
Awarded by Australian NHMRC-EU
Awarded by Medical Research Council
Awarded by MRC
Awarded by Wellcome Trust
Awarded by National Health and Medical Research Council of Australia
Funding Acknowledgements
This project (CUTHIVAC) was funded by the European Union's Seventh Programme for research, technological development, and demonstration under grant agreement no. 241904, and the clinical conduct of the trial was supported by Imperial NIHR BRC. Provision of CN54 DNA-C and CN54gp140 was supported through core funding from the Wellcome Trust via UKHVC (083844/Z/07/Z). We gratefully acknowledge Dormeur Investment Service Ltd. for providing funds to purchase equipment used in these studies. Additional immunological assays were funded by the European Union's Horizon 2020 research and innovation programme under grant agreement no. 681032 and The Fc-functional antibody work by an Australian NHMRC-EU collaborative grant #1115828. S.M.C was supported by the Medical Research Council (MRC_UU_12023/23).